Crossmark

Trastuzumab in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: feasibility and preliminary efficacy

Crossref DOI link: https://doi.org/10.1007/s00280-015-2807-7

Published Online: 2015-06-23

Published Print: 2015-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mitsui, Yasuhiro

Sato, Yasushi

Miyamoto, Hiroshi

Fujino, Yasuteru

Takaoka, Toshi

Miyoshi, Jinsei

Kagawa, Miwako

Ohnuma, Hiroyuki

Hirakawa, Masahiro

Kubo, Tomohiro

Osuga, Takahiro

Sagawa, Tamotsu

Sato, Yasuhiro

Takahashi, Yasuo

Katsuki, Shinich

Okuda, Toshinori

Takimoto, Rishu

Kobune, Masayoshi

Nobuoka, Takayuki

Hirata, Koichi

Kato, Junji

Takayama, Tetsuji
Funding

Funding for this research was provided by:

TAIHO pharmaceutical Co.,Ltd (Tokyo, Japan) (K171300050)
License Information

Text and Data Mining valid from 2015-06-23

Document is current

Any future updates will be listed below